DIHYDROERGOTAMINE MESYLATE by Cipla is 5-ht 1dα and 5-ht 1dβ receptors. Approved for hemiplegic migraine, migraine with brainstem aura. First approved in 2024.
Drug data last refreshed 19h ago
5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Worked on DIHYDROERGOTAMINE MESYLATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.